Molecular targeted therapy for advanced or metastatic soft tissue sarcoma

Soft tissue sarcomas are a form of rare and heterogeneous neoplasms with high recurrence rate and mortality. Over the past decades, less progress has been achieved. Surgical management with or without adjuvant/neoadjuvant radiotherapy is still the first-line treatment for localized soft tissue sarco...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jin Yuan MD, Xiaoyang Li MD, PhD, Shengji Yu MD
Formato: article
Lenguaje:EN
Publicado: SAGE Publishing 2021
Materias:
Acceso en línea:https://doaj.org/article/9bcc089f4fd74fe2bc7610c1056457c1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:9bcc089f4fd74fe2bc7610c1056457c1
record_format dspace
spelling oai:doaj.org-article:9bcc089f4fd74fe2bc7610c1056457c12021-12-01T23:07:06ZMolecular targeted therapy for advanced or metastatic soft tissue sarcoma1073-274810.1177/10732748211038424https://doaj.org/article/9bcc089f4fd74fe2bc7610c1056457c12021-11-01T00:00:00Zhttps://doi.org/10.1177/10732748211038424https://doaj.org/toc/1073-2748Soft tissue sarcomas are a form of rare and heterogeneous neoplasms with high recurrence rate and mortality. Over the past decades, less progress has been achieved. Surgical management with or without adjuvant/neoadjuvant radiotherapy is still the first-line treatment for localized soft tissue sarcomas, and chemotherapy is the additional option for those with high-risk. However, not all patients with advanced or metastatic soft tissue sarcomas benefit from conventional chemotherapy, targeted therapy takes the most relevant role in the management of those resistant to or failed to conventional chemotherapy. Heterogeneous soft tissue sarcomas vary from biological behavior, genetic mutations, and clinical presentation with a low incidence, indicating the future direction of histotype-based even molecule-based personalized therapy. Furthermore, increasing preclinical studies were carried out to investigate the pathogenesis and potential therapeutic targets of soft tissue sarcomas and increasing new drugs have been developed in recent years, which had started opening new doors for clinical treatment for patients with advanced/metastatic soft tissue sarcomas. Here we sought to summarize the concise characteristics and advance in the targeted therapy for the most common subtypes of soft tissue sarcomas.Jin Yuan MDXiaoyang Li MD, PhDShengji Yu MDSAGE PublishingarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancer Control, Vol 28 (2021)
institution DOAJ
collection DOAJ
language EN
topic Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
spellingShingle Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Jin Yuan MD
Xiaoyang Li MD, PhD
Shengji Yu MD
Molecular targeted therapy for advanced or metastatic soft tissue sarcoma
description Soft tissue sarcomas are a form of rare and heterogeneous neoplasms with high recurrence rate and mortality. Over the past decades, less progress has been achieved. Surgical management with or without adjuvant/neoadjuvant radiotherapy is still the first-line treatment for localized soft tissue sarcomas, and chemotherapy is the additional option for those with high-risk. However, not all patients with advanced or metastatic soft tissue sarcomas benefit from conventional chemotherapy, targeted therapy takes the most relevant role in the management of those resistant to or failed to conventional chemotherapy. Heterogeneous soft tissue sarcomas vary from biological behavior, genetic mutations, and clinical presentation with a low incidence, indicating the future direction of histotype-based even molecule-based personalized therapy. Furthermore, increasing preclinical studies were carried out to investigate the pathogenesis and potential therapeutic targets of soft tissue sarcomas and increasing new drugs have been developed in recent years, which had started opening new doors for clinical treatment for patients with advanced/metastatic soft tissue sarcomas. Here we sought to summarize the concise characteristics and advance in the targeted therapy for the most common subtypes of soft tissue sarcomas.
format article
author Jin Yuan MD
Xiaoyang Li MD, PhD
Shengji Yu MD
author_facet Jin Yuan MD
Xiaoyang Li MD, PhD
Shengji Yu MD
author_sort Jin Yuan MD
title Molecular targeted therapy for advanced or metastatic soft tissue sarcoma
title_short Molecular targeted therapy for advanced or metastatic soft tissue sarcoma
title_full Molecular targeted therapy for advanced or metastatic soft tissue sarcoma
title_fullStr Molecular targeted therapy for advanced or metastatic soft tissue sarcoma
title_full_unstemmed Molecular targeted therapy for advanced or metastatic soft tissue sarcoma
title_sort molecular targeted therapy for advanced or metastatic soft tissue sarcoma
publisher SAGE Publishing
publishDate 2021
url https://doaj.org/article/9bcc089f4fd74fe2bc7610c1056457c1
work_keys_str_mv AT jinyuanmd moleculartargetedtherapyforadvancedormetastaticsofttissuesarcoma
AT xiaoyanglimdphd moleculartargetedtherapyforadvancedormetastaticsofttissuesarcoma
AT shengjiyumd moleculartargetedtherapyforadvancedormetastaticsofttissuesarcoma
_version_ 1718404002222178304